Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes
Article first published online: 16 MAY 2007
Copyright © 2007 John Wiley & Sons, Ltd.
Diabetes/Metabolism Research and Reviews
Volume 24, Issue 1, pages 41–51, January 2008
How to Cite
Albarracin, C. A., Fuqua, B. C., Evans, J. L. and Goldfine, I. D. (2008), Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab. Res. Rev., 24: 41–51. doi: 10.1002/dmrr.755
- Issue published online: 11 DEC 2007
- Article first published online: 16 MAY 2007
- Manuscript Accepted: 1 APR 2007
- Manuscript Revised: 28 FEB 2007
- Manuscript Received: 8 NOV 2006
- hemoglobin A1C
Chromium and biotin play essential roles in regulating carbohydrate metabolism. This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the combination of chromium picolinate and biotin on glycaemic control.
Four hundred and forty-seven subjects with poorly controlled type 2 diabetes (HbA1c ≥ 7.0%) were enrolled and received either chromium picolinate (600 µg Cr+3) with biotin (2 mg), or matching placebo, for 90 days in combination with stable oral anti-diabetic agents (OADs). Major endpoints were reductions in HbA1c, fasting glucose, and lipids. Safety and tolerability were assessed.
Change in HbA1c was significantly different between treatment groups (p = 0.03). HbA1c in the chromium picolinate/biotin group decreased 0.54%. The decrease in HbA1c was most pronounced in chromium picolinate/biotin subjects whose baseline HbA1c ≥ 10%, and highly significant when compared with placebo (−1.76% vs − 0.68%; p = 0.005). Fasting glucose levels were reduced in the entire chromium picolinate/biotin group versus placebo (−9.8 mg/dL vs 0.7 mg/dL; p = 0.02). Reductions in fasting glucose were also most marked in those subjects whose baseline HbA1c ≥ 10.0%, and significant when compared to placebo (−35.8 mg/dL vs. 16.2 mg/dL; p = 0.01). Treatment was well tolerated with no adverse effects dissimilar from placebo.
These results suggest that the chromium picolinate/biotin combination, administered as an adjuvant to current prescription anti-diabetic medication, can improve glycaemic control in overweight to obese individuals with type 2 diabetes; especially those patients with poor glycaemic control on oral therapy. Copyright © 2007 John Wiley & Sons, Ltd.